

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-22. (Canceled)

- ~~1~~²³ (Currently amended). An isolated antibody or antigen binding fragment thereof which:
- (a) specifically binds a factor IX/IXa Gla domain; and
 - (b) comprises a heavy chain and a light chain variable region further wherein:
 - (i) the heavy chain variable region comprises a CDR1 which is SEQ ID NO:10, a CDR2 which is SEQ ID NO:11 and a CDR3 which is SEQ ID NO:12; and
 - (ii) the light chain variable region comprises ~~an~~ a CDR1 which is SEQ ID NO:13, ~~and~~ le a CDR2 which is SEQ ID NO:14, and ~~an~~ a CDR3 which is SEQ ID NO:15.
- ~~2~~²⁴ (Previously presented). A composition comprising the antibody or antigen binding fragment of Claim ~~23~~¹ and a carrier, excipient or stabilizer.
- ~~3~~²⁵ (Previously presented). The composition of Claim ~~24~~², wherein the carrier, excipient or stabilizer is pharmaceutically-acceptable.
- ~~4~~²⁶ (Previously presented). The composition of Claim ~~25~~³, which is sterile.
- ~~5~~²⁷ (Previously presented). The composition of Claim ~~26~~⁴ further comprising a thrombolytic agent.
- ~~6~~²⁸ (Previously presented). The composition of Claim ~~27~~⁵ wherein the thrombolytic agent is tissue plasminogen activator.
- ~~7~~²⁹ (Previously presented). The composition of Claim ~~28~~⁵ wherein the thrombolytic agent is streptokinase.
- ~~8~~³⁰ (Previously presented). The composition of Claim ~~29~~⁵ wherein the thrombolytic agent is urokinase.

⁹~~31~~ (Previously presented). The composition of Claim ⁵~~27~~ wherein the thrombolytic agent is an isolated streptokinase plasminogen.

¹⁰~~32~~ (Previously presented). The composition of Claim ⁴~~26~~ which is lyophilized.

¹¹~~33~~ (Previously presented). The composition of Claim ⁴~~26~~ which is liquid.

¹²~~34~~ (Previously presented). The composition of Claim ⁵~~27~~ which is lyophilized.

¹³~~35~~ (Previously presented). The composition of Claim ⁵~~27~~ which is liquid.

¹⁴~~36~~ (Previously presented). An article of manufacture comprising;

(a) a container;

(b) a label on said container; and

(c) a composition comprising an antibody or antibody fragment of Claim ¹~~23~~ within said container;

wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulopathic disorder.

¹⁵~~37~~ (Previously presented). An article of manufacture comprising:

(a) a container;

(b) a label on said container; and

(c) the composition of Claim ⁴~~26~~ within said container;

wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulopathic disorder.

¹⁶~~38~~ (Previously presented). An article of manufacture comprising:

- (a) a container;
- (b) a label on said container; and
- (c) the composition of Claim ~~27~~⁵ within said container;

wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulopathic disorder.

~~17~~³⁹ (Previously presented). An article of manufacture comprising:

- (a) a container;
- (b) a label on said container; and
- (c) the composition of Claim ~~28~~⁶ within said container; wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulopathic disorder.

~~18~~⁴⁰ (Previously presented). An article of manufacture comprising:

- (a) a container;
- (b) a label on said container; and
- (c) the composition of Claim ~~29~~⁷ within said container;

wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulopathic disorder.

~~19~~⁴¹ (Previously presented). An article of manufacture comprising:

- (a) a container;
- (b) a label on said container; and
- (c) the composition of Claim ~~30~~⁸ within said container;

Appl. No. 10/614,959

Patent Docket P1661R2

Amend. dated August 22, 2005

Response to Office Action mailed on: April 20, 2005

wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulopathic disorder.

~~20~~
~~42~~ (Previously presented). An article of manufacture comprising:

- (a) a container;
- (b) a label on said container; and
- (c) the composition of Claim ~~31~~⁹ within said container;

wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulopathic disorder.